Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 23 of 28.
Oct 2010
27 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 72426.36 lacs for quarter ending on 30-SEP-2010 against Rs. 59032.61 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 11162.5 lacs for the quarter ending on 30-SEP-2010 against Rs. 8088.51 lacs for the quarter ending on 30-SEP-2009.18 Oct · Board meeting
To consider and approve the Un-Audited Financial Results for the Second Quarter/Half year ended September 30, 2010.1 Oct · Disclosure
At the Compensation Committee held on September 24, 2010 has allotted 1,11,000 stock options to the permanent employees pursuant to ESOS 2003.
Sep 2010
29 Sep · Business
Board of Directors of the Company, at its Operations Committee Meeting held on September 27, 2010 allotted 29,200 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.27 Sep · Meeting
At the Annual General Meeting held on September 27, 2010, the shareholders have approved the following: (1) Final Dividend @ 40% on the Equity Share Capital of the Company for the financial year ended 2009-2010.(2) Appointment of Walker, Chandiok & Co, Chartered Accountants as Statutory Auditors of the Company for the Financial Year 2010-2011.1 Sep · Meeting
Register of Members and the Share Transfer Books of the Company will remain closed from September 20, 2010 to September 27, 2010 (both days inclusive) for the purpose of the Annual Closure for the Annual General Meeting scheduled to be held on September 27, 2010 and also for determining the names of the shareholders to whom the dividend which if declared at the Annual General Meeting is payable.
Aug 2010
25 Aug · Business
Board of Directors of the Company, at its Operations Committee Meeting held on August 24, 2010 allotted 38,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.10 Aug · Business
Board of Directors of the Company, at its Meeting held on August 09, 2010 allotted 62,300 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Jul 2010
27 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 25700.02 lacs for quarter ending on 30-JUN-2010 against Rs. 21995.92 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 6079.11 lacs for the quarter ending on 30-JUN-2010 against Rs. 522 lacs for the quarter ending on 30-JUN-2009.27 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 68186.01 lacs for quarter ending on 30-JUN-2010 against Rs. 54368.76 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 15554.37 lacs for the quarter ending on 30-JUN-2010 against Rs. 5345.46 lacs for the quarter ending on 30-JUN-2009.16 Jul · Board meeting
To consider and approve the Un-audited Financial Results for the First Quarter ended June 30, 2010.12 Jul · Business
Board of Directors of the Company, at its Operations Committee Meeting held today i.e. on July 10, 2010 allotted 7,400 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Jun 2010
4 Jun · Disclosure
Board of Directors of the Company, at its Operations Committee Meeting held today i.e. on June 04, 2010 allotted 27,800 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
May 2010
28 May · Dividend
Board of Directors, at their meeting held on May 28, 2010, has recommended Dividend @ 40% i.e. Re.0.40 per share (face value Re.1/-) on the Equity Share Capital of the Company for the financial year 2009-2010 subject to the approval of Shareholders at the Annual General Meeting.28 May · Results
Consolidated Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 70914.73 lacs for quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 10261.85 lacs for the quarter ending on 31-MAR-2010.28 May · Results
Standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 28919.98 lacs for quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 2825.62 lacs for the quarter ending on 31-MAR-2010.28 May · Results
Standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 102191.05 lacs for year ending on 31-MAR-2010 against Rs. 85529.13 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 12846.32 lacs for the year ending on 31-MAR-2010 against Rs. 21792.63 lacs for the year ending on 31-MAR-2009.28 May · Results
Consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 248484.55 lacs for year ending on 31-MAR-2010 against Rs. 209301.68 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 33103.16 lacs for the year ending on 31-MAR-2010 against Rs. 19347.29 lacs for the year ending on 31-MAR-2009.17 May · Board meeting
Inter alia, to consider the following : (1) To consider and approve the Company's audited financial statements for the 4th quarter and year ended March 31, 2010; (2) To consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2010.17 May · Updates
Forest Laboratories Inc. USA and Glenmark Pharmaceuticals, on May 15, 2010, announced that topline results from Oglemilast (GRC 3886) did not meet the primary endpoint in its Phase IIb study on Asthma patients. Forest and Glenmark would discuss further course of action regarding Oglemilast.11 May · Results
Audited Financial Results of the Company for the financial year ended March 31, 2010 would be published on or before May 30, 2010. Hence, the Company would not be publishing the Un-audited Financial Results for the last quarter ended March 31, 2010.10 May · Business
Board of Directors of the Company, at its Operations Committee Meeting held on May 10, 2010 allotted 21,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Apr 2010
29 Apr · Business
Press release dated April 29, 2010, titled "Glenmark launches Prasugrel for the first time in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.